Passa al contenuto
Merck
Tutte le immagini(1)

Key Documents

1420006

USP

Levodopa Related Compound B

United States Pharmacopeia (USP) Reference Standard

Sinonimo/i:

DL-3-O-Methyldopa, 3-Methoxytyrosine

Autenticatiper visualizzare i prezzi riservati alla tua organizzazione & contrattuali
Tutte le immagini(1)

About This Item

Formula empirica (notazione di Hill):
C10H13NO4
Numero CAS:
7636-26-2
Peso molecolare:
211.21
Codice UNSPSC:
41116107
NACRES:
NA.24

Grado

pharmaceutical primary standard

Famiglia di API

levodopa

Produttore/marchio commerciale

USP

applicazioni

pharmaceutical (small molecule)

Formato

neat

InChI

1S/C10H13NO4/c1-15-9-5-6(2-3-8(9)12)4-7(11)10(13)14/h2-3,5,7,12H,4,11H2,1H3,(H,13,14)
PFDUUKDQEHURQC-UHFFFAOYSA-N

Cerchi prodotti simili? Visita Guida al confronto tra prodotti

Categorie correlate

Descrizione generale

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

Applicazioni

Levodopa Related Compound B USP reference standard, intended for use in specified quality tests and assays as specified in the USP compendia.
Also, for use with USP monographs such as:
  • Carbidopa and Levodopa Orally Disintegrating Tablets
  • Levodopa
  • Carbidopa and Levodopa Tablets
  • Carbidopa and Levodopa Extended-Release Tablets

Risultati analitici

These products are for test and assay use only. They are not meant for administration to humans or animals and cannot be used to diagnose, treat, or cure diseases of any kind.  ​

Altre note

Sales restrictions may apply.

Codice della classe di stoccaggio

11 - Combustible Solids

Classe di pericolosità dell'acqua (WGK)

WGK 3

Punto d’infiammabilità (°F)

Not applicable

Punto d’infiammabilità (°C)

Not applicable

Certificati d'analisi (COA)

Cerca il Certificati d'analisi (COA) digitando il numero di lotto/batch corrispondente. I numeri di lotto o di batch sono stampati sull'etichetta dei prodotti dopo la parola ‘Lotto’ o ‘Batch’.

Possiedi già questo prodotto?

I documenti relativi ai prodotti acquistati recentemente sono disponibili nell’Archivio dei documenti.

Visita l’Archivio dei documenti

I clienti hanno visto anche

Slide 1 of 8

1 of 8

Methyldopa United States Pharmacopeia (USP) Reference Standard

USP

1426002

Methyldopa

3,4-dihydroxyphenylacetone 95%

Sigma-Aldrich

796883

3,4-dihydroxyphenylacetone

Levodopa European Pharmacopoeia (EP) Reference Standard

L0400000

Levodopa

L-Dopa-(phenyl-d3) ≥98 atom % D, ≥98% (CP)

Sigma-Aldrich

333786

L-Dopa-(phenyl-d3)

Levodopa Pharmaceutical Secondary Standard; Certified Reference Material

Supelco

PHR1271

Levodopa

3,4-Dihydroxybenzaldehyde 97%

Sigma-Aldrich

D108405

3,4-Dihydroxybenzaldehyde

Serotonin analytical standard

Supelco

14927

Serotonin

3,4-Dihydroxy-L-phenylalanine ≥98% (TLC)

Sigma-Aldrich

D9628

3,4-Dihydroxy-L-phenylalanine

Angela Zampella et al.
Organic letters, 7(16), 3585-3588 (2005-07-29)
All stereoisomers of beta-methoxytyrosine (beta-OMeTyr), a stereo-undefined component of callipeltin A, were synthesized from L- and D-tyrosine. The stereochemistry of beta-OMeTyr in callipeltin A was determined to be 2R,3R by an oxidative procedure and Marfey's analysis. [structure: see text]
Eun-Sook Y Lee et al.
Neurochemical research, 33(3), 401-411 (2007-08-24)
Long-term treatment of L-dopa for Parkinson's disease (PD) patients induces adverse effects, including dyskinesia, on-off and wearing-off symptoms. However, the cause of these side effects has not been established to date. In the present study, therefore, 3-O-methyldopa (3-OMD), which is
Aiko Ishihara et al.
Hiroshima journal of medical sciences, 60(3), 57-62 (2011-11-08)
The aim of this study is to clarify the relationship between serum 3-O-methyldopa (3-OMD) and the clinical effects of entacapone. The 3-OMD and maximum serum concentration (Cmax) of levodopa were measured in 21 Parkinson's Disease patients who took 100 mg
Eun-Sook Y Lee et al.
Neurotoxicology, 26(3), 361-371 (2005-06-07)
Long-term treatment of levodopa for Parkinson's disease (PD) patients is known to elevate homocysteine level in their plasma. The present study was designed to examine the possible neurotoxic effects of the increased homocysteine level on the dopaminergic system. Homocysteine was
Li-Hsuan Wang et al.
Phytotherapy research : PTR, 24(6), 852-858 (2009-11-27)
The impacts of caffeic acid (3,4-dihydroxycinnamic acid, CA) on the pharmacokinetics of levodopa (L-dopa) were studied in rabbits. A single dose of 5/1.25 mg kg(-1) L-dopa/carbidopa was administered alone or was co-administered with three different doses of caffeic acid (2.5
Visualizza tutti i documenti correlati

Il team dei nostri ricercatori vanta grande esperienza in tutte le aree della ricerca quali Life Science, scienza dei materiali, sintesi chimica, cromatografia, discipline analitiche, ecc..

Contatta l'Assistenza Tecnica.